Loading insider details...
Beta
Latest Form 4 (Jun 15, 2026): Grant/Award of 87,900 FATE shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | FATE THERAPEUTICS INC (FATE) | Grant/Award | 87,900 | n/a |
| Jun 12, 2026 | Xilio Therapeutics, Inc. (XLO) | Grant/Award | 5,000 | n/a |
| Dec 9, 2025 | Akero Therapeutics, Inc. (AKRO) | Disposition to Issuer | 9,398 | n/a |
| Jun 12, 2025 | Xilio Therapeutics, Inc. (XLO) | Grant/Award | 31,000 | n/a |
| Jun 5, 2025 | Akero Therapeutics, Inc. (AKRO) | Grant/Award | 9,398 | n/a |
| May 30, 2025 | FATE THERAPEUTICS INC (FATE) | Grant/Award | 55,000 | n/a |
| Aug 7, 2024 | FATE THERAPEUTICS INC (FATE) | Sale | 633 | $2.7K |
| Jun 17, 2024 | Xilio Therapeutics, Inc. (XLO) | Grant/Award | 25,000 | n/a |
| Jun 11, 2024 | Akero Therapeutics, Inc. (AKRO) | Grant/Award | 26,000 | n/a |
| Jun 11, 2024 | FATE THERAPEUTICS INC (FATE) | Grant/Award | 40,000 | n/a |